NO951433L - Kjemiske forbindelser - Google Patents

Kjemiske forbindelser

Info

Publication number
NO951433L
NO951433L NO951433A NO951433A NO951433L NO 951433 L NO951433 L NO 951433L NO 951433 A NO951433 A NO 951433A NO 951433 A NO951433 A NO 951433A NO 951433 L NO951433 L NO 951433L
Authority
NO
Norway
Prior art keywords
formula
alkyl
hydrogen
different
same
Prior art date
Application number
NO951433A
Other languages
English (en)
Other versions
NO951433D0 (no
Inventor
Peter Charles North
Sjoerd Nicolaas Wadman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO951433L publication Critical patent/NO951433L/no
Publication of NO951433D0 publication Critical patent/NO951433D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/04Nitro compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Denne oppfinnelse vedrører benzofuranderivater, frem- gangsmåter for deres fremstilling, farmasøytiske blandinger inneholdende dem og deres medisinske anvendelse, spesielt forbindelser og blandinger for bruk ved behandling av migrene. Spesielt tilveiebringer oppfinnelsen en forbindelse med formel (I) hvori R1 er -CH2CONR3R*; R2 er -CH2CH2NR5R6; R3 og R*, sammen med N-atomet som de er knyttet til, danner en mettet 4- til 7- leddet ring med formelen (II), hvor Z er en gruppe med formelen -CR7R8-, -O- eller -NR9-; R5 og R6, som kan være like eller forskjellige, er hydrogen eller Cj^alkyl; R7 og R8, som kan være like eller forskjellige, er hydrogen, hydroksy eller C^alkoksy; R» er -S02R10, -COR10 eller -COOR10; R10 er C^alkyl; og farmasøytisk akseptable salter og solvater derav.
NO951433A 1992-10-16 1995-04-12 Kjemiske forbindelser NO951433D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929221761A GB9221761D0 (en) 1992-10-16 1992-10-16 Chemical compounds
PCT/EP1993/002833 WO1994008993A1 (en) 1992-10-16 1993-10-14 Benzofuran derivatives as 5-ht1-like receptor antagonists

Publications (2)

Publication Number Publication Date
NO951433L true NO951433L (no) 1995-04-12
NO951433D0 NO951433D0 (no) 1995-04-12

Family

ID=10723562

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951433A NO951433D0 (no) 1992-10-16 1995-04-12 Kjemiske forbindelser

Country Status (24)

Country Link
US (1) US5494910A (no)
EP (1) EP0664804A1 (no)
JP (1) JPH06211842A (no)
KR (1) KR940009179A (no)
CN (1) CN1092420A (no)
AP (1) AP425A (no)
AU (1) AU5333794A (no)
CA (1) CA2146569A1 (no)
CZ (1) CZ96895A3 (no)
EC (1) ECSP941050A (no)
FI (1) FI951798A (no)
GB (1) GB9221761D0 (no)
HU (1) HUT72752A (no)
IL (1) IL107302A0 (no)
IS (1) IS4081A (no)
MX (1) MX9306394A (no)
NO (1) NO951433D0 (no)
PE (1) PE51294A1 (no)
PL (1) PL308357A1 (no)
RU (1) RU95110110A (no)
SI (1) SI9300542A (no)
TW (1) TW262473B (no)
WO (1) WO1994008993A1 (no)
ZA (1) ZA937633B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407447D0 (en) * 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
EP0759918A1 (en) * 1994-05-19 1997-03-05 MERCK SHARP & DOHME LTD. Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
GB9610979D0 (en) * 1996-05-24 1996-07-31 Merck Sharp & Dohme Therapeutic agents
AU4652697A (en) * 1996-10-08 1998-05-05 Eli Lilly And Company New serotonin 5-ht1f agonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
PL2734634T3 (pl) 2011-07-22 2020-03-31 The University Of Chicago Igf-1 do zastosowania do leczenia migreny
KR101443041B1 (ko) * 2013-05-06 2014-09-23 (주)하이레벤 태양광 발전설비의 효율향상설비
KR20240058859A (ko) 2021-08-12 2024-05-03 쿨레온 엘엘씨 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670105A1 (de) * 1966-07-08 1970-12-10 Byk Gulden Lomberg Chem Fab Verfahren zur Herstellung von Benzofuryl (3)-alkylaminen und deren Salzen
EP0398413A1 (en) * 1989-05-16 1990-11-22 Duphar International Research B.V "3,4-dehydropiperidine derivatives having psychotropic activity

Also Published As

Publication number Publication date
AP9300581A0 (en) 1993-10-31
US5494910A (en) 1996-02-27
MX9306394A (es) 1994-05-31
HU9501073D0 (en) 1995-06-28
RU95110110A (ru) 1996-12-27
CA2146569A1 (en) 1994-04-28
HUT72752A (en) 1996-05-28
KR940009179A (ko) 1994-05-20
WO1994008993A1 (en) 1994-04-28
SI9300542A (en) 1994-06-30
PE51294A1 (es) 1995-01-06
TW262473B (no) 1995-11-11
IS4081A (is) 1994-04-17
FI951798A0 (fi) 1995-04-13
PL308357A1 (en) 1995-07-24
AU5333794A (en) 1994-05-09
ZA937633B (en) 1994-08-01
JPH06211842A (ja) 1994-08-02
IL107302A0 (en) 1994-01-25
FI951798A (fi) 1995-04-13
GB9221761D0 (en) 1992-12-02
EP0664804A1 (en) 1995-08-02
CN1092420A (zh) 1994-09-21
CZ96895A3 (en) 1995-12-13
NO951433D0 (no) 1995-04-12
ECSP941050A (es) 1994-11-16
AP425A (en) 1995-11-08

Similar Documents

Publication Publication Date Title
NO951266L (no) Imidazol-holdige inhibitorer for farnesyl-protein-transferase
NO20061170L (no) Piperazinderivater for behandling av HIV-infeksjoner
DK157678C (da) Analogifremgangsmaade til fremstilling af amider af hydroxyfenylalkylaminoaetanoler eller terapeutisk acceptable salte deraf samt acetofenonderivat til anvendelse som udgangsmateriale ved fremgangsmaaden
NO331068B1 (no) Benzazepinderivater for behandling av nevrologiske forstyrrelser.
NO951433L (no) Kjemiske forbindelser
HUP0302526A2 (hu) Makrolid vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
KR940701264A (ko) 안과질환에 대한 마크로라이드 화합물의 용도
MY105402A (en) 17-beta-substituted-4-aza-5alpha-androstan-3-one derivatives and process for their preparation.
HUP0401886A2 (hu) Kemokin receptor aktivitás modulátorokként alkalmazható piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BG101402A (en) Apoliprotein-b synthesis inhibitors
HUT71804A (en) 11,21-bisphenyl-19-norpregnane derivatives, pharmaceutical compositions, process for producing them
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
GB0117396D0 (en) Chemical compounds
EP1277744A4 (en) OXADIAZONE DERIVATIVES WITH ANTIBODY EFFECT
HUP0102031A2 (hu) Széles spektrumú gombásodásgátló hatású vízoldható azolok, eljárás az előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
NO994659L (no) Nye pyridinderivater og farmasöytiske preparater inneholdende slike
NO990335L (no) Arylsykloalkankarboksylestere, anvendelse derav, farmas°ytiske sammensetninger og fremstilling
NO20045132L (no) Benzo(c)kinolizinderivater, deres fremstilling og anvendelse som 5alfa- reduktaseinhibitorer
FI88393C (fi) Foerfarande foer framstaellning av 17-substituerade androsta-1,4-dien-3-onderivat
ES2010145A6 (es) Procedimiento para la obtencion de derivados de la 2-picolilamina.
NO20045540L (no) Nye 3-(4-okso-4H-kromen-2-yl)-(1H)-kinolin-4-on-forbindelser, en fremgangsmate for deres fremstilling og farmasoytisk sammensetninger inneholdende dem
NO180443C (no) Oktahydronaftalenoksimderivater samt farmasöytiske preparater som omfatter et slikt derivat til inhibering av kolesterolbiosyntese
NO20000424L (no) Streptograminer, deres fremstilling samt preparater inneholdende forbindelsene
NO20003431L (no) Nye metalloproteaseinhibitorer, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem
NO982549L (no) 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav